Full Text
The cost-effectvenese of liraglutide vs exenatide for the treatment of type 2 diabetes in the United States

Abstract

Authors

N. Ning J.W. Hay

Back to Volume 17, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×